Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19020373 | 0.93 | PPARA (0.54) | KLK5PPARACTSKSIRT2SIRT1 | |
| SCHEMBL2301376 | 0.93 | PPARA (0.54) | KLK5PPARACTSKSIRT2SIRT1 | |
| SCHEMBL17446701 | 0.93 | PPARA (0.54) | KLK5PPARACTSKSIRT2SIRT1 | |
| SCHEMBL8178286 | 0.92 | PPARA (0.58) | KLK5PPARACTSKSIRT2SIRT1 | |
| SCHEMBL8177426 | 0.92 | PPARA (0.58) | KLK5PPARACTSKSIRT2SIRT1 | |
| SCHEMBL5970500 | 0.91 | PPARA (0.52) | KLK5PPARACTSKKLK7CTSS | |
| SCHEMBL23153704 | 0.88 | CTSS (0.54) | KLK5PPARACTSKKLK7CTSS | |
| SCHEMBL22404783 | 0.88 | CTSK (0.49) | KLK5PPARACTSKKLK7CTSS | |
| SCHEMBL25985265 | 0.88 | CTSK (0.49) | KLK5PPARACTSKKLK7CTSS | |
| SCHEMBL31106340 | 0.88 | PPARA (0.51) | KLK5PPARACTSKSIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5925624-A | ANTIINFLAMMATORY AGENTS TREATING PATIENTS WITH INFLAMMATORY CONDITIONS SUSCEPTIBLE TO LEUKOCYTE-INDUCED TISSUE DAMAGE | GLAXO GROUP LIMITED (GB) | 1999-07-20 | — | — | US | disclosed |
| US-5889178-A | N-(2,2-DIPHENYLETHYL)-DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-03-30 | — | — | US | disclosed |